CatalystWireBeta

UK small-cap RNS · 2 Jul 2026

Every announcement of UK small & mid caps under £2bn. The ones that started or moved a situation are marked – a click opens it.

Sort: Newest · Largest companies
  1. 14:00
  2. 09:15
    Team TEAM £18m
    Director/PDMR Shareholding Director dealing
  3. 07:24
    Capricorn Energy CNE £291m
    Recommended cash acquisition of Capricorn by Genel Offer
    Genel's recommended cash offer is worth US$4.74 per share (357p), a 34% premium to the undisturbed price and 48% to the three-month VWAP. It follows the unsolicited Cafani approaches and is backed by 39.3% irrevocables.
    Takeover target £271.0m · 93% of mcapnext step +19.8% on the day
    Moved: new: Offer for the company – Recommended cash offer announced 2 July 2026 · Modernised concession agreement ratification: Parliament ratified; ministerial signature pending → Ratified; ministerial signature still pending
  4. 07:01
    PureTech Health PRTC £268m
    PRTC Launches Celea w/ $180M & Top Tier Syndicate
    PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)
    Disposal of a part (break-up) outlook positive −5.9% on the day
    Moved: Deupirfenidone IPF Phase 3: Financing completed; Phase 3 start planned early Q3 2026 → Financing completed; Phase 3 start early Q3 2026
  5. 07:00
    ECO Animal Health Group EAH £64m
    EU launch of ECOVAXXIN® MS
    ECO Animal Health Group plc (AIM: EAH), a leading global animal health company marketing and developing branded veterinary products to improve livestock productivity and welfare, announces the commercial launch of ECOVAXXIN® MS, its poultry vaccine against …
    Project milestones +3.2% on the day
    Moved: ECOVAXXIN MS EU approval and launch: EU marketing authorisation granted; launch planning → EU commercial launch completed in Madrid (closed)
  6. 07:00
    PureTech Health PRTC £268m
    $180M & Asset Transfer
    Closes the Celea financing that had slipped from H1 to early Q3 2026. Third-party money now funds the Phase 3 and removes the programme's spend (about $31.0m of external R&D in 2025) from PureTech's accounts, while it keeps 35.4%.
    Disposal of a part (break-up) outlook positivefirst since Oct 2023 −5.9% on the day
    Moved: Close Celea financing by H1 2026 (originally early 2026): delayed → delivered – Celea's $180m financing is announced as completed on 2 July 2026, after slipping past the end-H1 2026 target. · Deupirfenidone IPF Phase 3: Financing substantially complete, non-binding; close early Q3 2026 → Financing completed; Phase 3 start planned early Q3 2026
  7. 07:00
    Baltic Classifieds Group BCG £786m
    Final Results Results
    Revenue +7%, operating profit +13% and a stable 78% EBITDA margin are solid. But FY growth of 7% equals H1's 7%, so no H2 step-up shows against December's guidance. Auto was flat and net debt rose.
    Capital return first in 12 months −5.8% on the day
    Moved: Capital return policy update: Buyback extended by up to €45m → Accelerated debt-funded buyback; 10% repurchased by mid-June · Estonian auto market tax headwind: Estonian car transactions down by half → Estonian car transactions -43%; trading improved from March · new: Debt-funded buyback leverage – €118.0m drawn; leverage 0.7x
  8. 07:00
    Trifast TRI £108m
    Final Results Results
    Results landed just ahead of the c.£16.0m EBIT consensus and the April trading update (£16.3m CER vs £16.0m). Nothing in the announcement raises guidance, so this is not an upgrade.
    Turnaround plan with targets in lineoutlook positivefirst in 11 months +2.6% on the day
    Moved: Malaysia manufacturing closure: Manufacturing exit from April 2026; hub retained → Exit done; supports leaner operating model
  9. 07:00
    Redcentric RCN £86m
    Update on Capital Reduction
    Court sanction of the Capital Reduction clears the legal step needed for the up-to-£90m tender offer, so the cash return funded by the data centre sale is on course.
    Capital return £90.0m · 104% of mcap +1.6% on the day
    Moved: Return of capital and debt reduction: Net cash £77.9m after sale; tender offer pending → Court sanctioned Capital Reduction; registration pending
  10. 07:00
    Concurrent Technologies CNC £250m
    $9.4m US Defence Production Order
    A 2024 design win moves into production with a $9.4m US defence order, as the company had flagged. Only $6.2m is firm product; $3.2m is a cancellable component commitment. The announcement gives $9.4m, not £13.6m.
    Transformational contract / build-out 6% of mcap +1.7% on the day
    Moved: new: US airborne ECM production programme – Production order placed; PIC deliveries 2026-27
  11. 07:00
    Currys CURY £1,473m
    Building an ever-stronger Currys
    Audited FY profit of £191m (+18%) confirms the May pre-announcement, just above the raised £180-190m guidance, with net cash £176m and EPS +19%; trading is solid and consensus is held.
    Capital return £50.0m · 3% of mcapin lineoutlook positivefirst in 6 months −1.3% on the day
    Moved: FY guidance and net cash: Figures reconfirmed; results due 2 July → Results confirmed £191m; comfortable with consensus · £50m share buyback: £74m returned to shareholders in the year; buyback completion not confirmed → Prior buyback done; new £50m starts
  12. 07:00
    Zephyr Energy ZPHR £65m
    Acquisition of further Paradox Basin acreage
    Buys a further 2,294 acres of Utah TLA leases north of the White Sands Unit, paid from existing cash. It builds on the 26 June land purchase and brings operated acreage to over 72,000 gross acres.
    Sale process / strategic review +6.7% on the day
    Moved: Paradox marketing / farm-in partner: Negotiations continuing; news expected within weeks → Acreage enlarged to over 72,000 acres; talks continue

Share this quote

Quote card
Post on X WhatsApp Download image

The link opens this announcement with the quote highlighted. Quotes are checked against the original text.

Add a note